CN101677555A - 治疗cb2受体介导的疼痛的方法 - Google Patents

治疗cb2受体介导的疼痛的方法 Download PDF

Info

Publication number
CN101677555A
CN101677555A CN200880016252A CN200880016252A CN101677555A CN 101677555 A CN101677555 A CN 101677555A CN 200880016252 A CN200880016252 A CN 200880016252A CN 200880016252 A CN200880016252 A CN 200880016252A CN 101677555 A CN101677555 A CN 101677555A
Authority
CN
China
Prior art keywords
aryl
halogen
replaced
hydroxyl
exist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880016252A
Other languages
English (en)
Chinese (zh)
Inventor
M·夏
C·M·弗洛尔斯
M·J·马切拉格
K·P·帕夫利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101677555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101677555A publication Critical patent/CN101677555A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880016252A 2007-03-21 2008-02-27 治疗cb2受体介导的疼痛的方法 Pending CN101677555A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89601707P 2007-03-21 2007-03-21
US60/896,017 2007-03-21
PCT/US2008/055102 WO2008115672A1 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Publications (1)

Publication Number Publication Date
CN101677555A true CN101677555A (zh) 2010-03-24

Family

ID=39766330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880016252A Pending CN101677555A (zh) 2007-03-21 2008-02-27 治疗cb2受体介导的疼痛的方法

Country Status (13)

Country Link
EP (1) EP2139327A4 (ja)
JP (1) JP2010522182A (ja)
KR (1) KR20090120500A (ja)
CN (1) CN101677555A (ja)
AR (1) AR065801A1 (ja)
AU (1) AU2008229265A1 (ja)
CA (1) CA2681384A1 (ja)
CL (1) CL2008000817A1 (ja)
MX (1) MX2009010164A (ja)
PE (1) PE20090551A1 (ja)
TW (1) TW200904414A (ja)
UY (1) UY30974A1 (ja)
WO (1) WO2008115672A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
IN2014MN00226A (ja) 2011-07-05 2015-09-25 Lupin Ltd

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548212A (en) * 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
CN1956964B (zh) * 2004-03-24 2011-06-15 詹森药业有限公司 四氢-吲唑大麻素调节剂
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
CN101312725B (zh) * 2005-09-23 2012-01-11 詹森药业有限公司 六氢-环辛四烯并吡唑大麻素调节剂

Also Published As

Publication number Publication date
PE20090551A1 (es) 2009-05-16
AU2008229265A1 (en) 2008-09-25
CL2008000817A1 (es) 2008-09-26
WO2008115672A1 (en) 2008-09-25
UY30974A1 (es) 2008-09-30
JP2010522182A (ja) 2010-07-01
EP2139327A1 (en) 2010-01-06
TW200904414A (en) 2009-02-01
MX2009010164A (es) 2009-10-12
KR20090120500A (ko) 2009-11-24
CA2681384A1 (en) 2008-09-25
AR065801A1 (es) 2009-07-01
EP2139327A4 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
Vardanyan et al. Synthesis of best-seller drugs
Nguyen et al. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
EP1485078B1 (en) Milnacipran for the treatment of irritable bowel syndrome
Feltenstein et al. NMDA receptor blockade in the basolateral amygdala disrupts consolidation of stimulus-reward memory and extinction learning during reinstatement of cocaine-seeking in an animal model of relapse
CN105377299B (zh) 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
Zhang et al. Non-opioid-dependent anti-inflammatory effects of low frequency electroacupuncture
TW200823196A (en) New use
AU2012258219A1 (en) Use of sigma ligands in diabetes type-2 associated pain
WO2007120485A2 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
AU2014255837A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
EP2510949A1 (en) Therapeutic agent for fibromyalgia
AU2022241458A1 (en) Use of phenoxypropylamine compounds to treat depression
MX2010012179A (es) Composicion farmaceutica para el tratamiento de eyaculacion prematura.
CN101296929A (zh) 适用作催产素受体促效剂的三环化合物
JPWO2018221551A1 (ja) ピラゾロキノリン誘導体を含有するレビー小体病治療剤
CN101677555A (zh) 治疗cb2受体介导的疼痛的方法
CN102046164A (zh) 烟碱性受体部分激动剂和乙酰胆碱酯酶抑制剂的组合、含有所述组合的药物组合物及其在治疗认知障碍中的用途
JPH11501051A (ja) 強迫性障害、睡眠時無呼吸、性的機能障害、嘔吐および乗物酔いの処置を意図する医薬
Krylova et al. Some aspects of investigation of the central mechanism of antinociceptive effect of a new analgetic from the hexaazaisowurtzitane group
KR20110005836A (ko) 과민성 방광의 치료를 위한 유데나필과 알푸조신 또는 옥시부티닌과의 복합제의 용도
JP2008512415A (ja) 中枢神経障害性疼痛の治療のためのアリール（またはヘテロアリール）アゾリルカルビノールの誘導体
CN101677556A (zh) 治疗cb2受体介导的疼痛的方法
EP4136072A1 (en) Compositions and methods for treating pain and/or inflammation
Sicuteri et al. Fenfluramine headache
US20090215850A1 (en) Method for treating cb2 receptor mediated pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100324